Page last updated: 2024-11-06

spiromustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID41945
CHEMBL ID27114
SCHEMBL ID11648500
MeSH IDM0064829

Synonyms (43)

Synonym
1,4-dione, 3-[2-[bis(2-chloroethyl)amino]ethyl]-
spirohydantoin mustard
SHM ,
56605-16-4
spiromustine
nsc172112
nsc-172112
speratine
brn 0757144
spiromustina [inn-spanish]
spiromustina [spanish]
1,3-diazaspiro(4.5)decane-2,4-dione, 3-(2-(bis(2-chloroethyl)amino)ethyl)-
3-(2-(bis(2-chloroethyl)amino)ethyl)-5,5-pentamethylenehydantoin
spiromustine [usan:inn]
nsc 172112
spiromustinum [inn-latin]
3-(2-(bis(2-chloroethyl)amino)ethyl)-1,3-diazaspiro(4.5)decane-2,4-dione
2-[2-[bis(2-chloroethyl)amino]ethyl]-2,4-diazaspiro[4.5]decane-1,3-dione
1, {3-diazaspiro[4.5]decane-2,4-dione,} {3-[2-[bis(2-chloroethyl)amino]ethyl]-}
3-(2-(bis(2-chloroethyl)amino)ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione
D05910
spiromustine (usan/inn)
NCI60_001387
CHEMBL27114
unii-j3hb83x76z
spiromustina
j3hb83x76z ,
spiromustinum
3-((2-((bis(2-chloroethyl)amino)ethyl))-1,3-diazaspiro(4,5)decane-2,4-dione
spiromustine [inn]
spiromustine [usan]
SCHEMBL11648500
3-(2-[bis(2-chloroethyl)amino]ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione #
QNKJFXARIMSDBR-UHFFFAOYSA-N
DTXSID20205171
HY-U00155
CS-7196
nci172112
nsc172112;nsc268497
Q27281152
MS-25088
3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione
AKOS040733835

Research Excerpts

Overview

Spiromustine is a hydantoin-containing nitrogen mustard currently in Phase I clinical trial. It was designed as a lipophilic compound capable of penetrating the CNS.

ExcerptReferenceRelevance
"Spiromustine is a new alkylating agent, of interest since it was rationally designed as a lipophilic compound capable of penetrating the CNS. "( Spiromustine: a new agent entering clinical trials.
Davignon, JP; Davis, RD; Marsoni, S; O'Dwyer, PJ; Plowman, J; Shoemaker, DD, 1983
)
3.15
"Spiromustine is a hydantoin-containing nitrogen mustard currently in Phase I clinical trial. "( Spiromustine analogues. Relationships between structure, plasma stability, and antitumor activity.
Driscoll, JS; Haces, A; Heideman, RL; Kelley, JA; Roth, JS, 1986
)
3.16

Pharmacokinetics

ExcerptReferenceRelevance
"A pediatric Phase I and pharmacokinetic study of the lipophilic alkylating agent spirohydantoin mustard (SHM) was conducted in 23 patients."( A pediatric phase I and pharmacokinetic study of spirohydantoin mustard.
Balis, F; Doherty, KM; Ettinger, LJ; Heideman, RL; Jeffries, SL; Kelley, JA; Packer, RJ; Poplack, DG; Reaman, GH; Roth, JS, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Four hours after dosing to rats and dogs, renal clearance of the ethyl-14C moiety (14--21%) is lower than that of the hydantoin-14C moiety (29--68%)."( The disposition of spirohydantoin mustard (NSC 172112) in rats and dogs.
Adamson, RH; Plowman, J, 1979
)
0.26
" Dose-response curves for exponentially growing and plateau-phase cells were similar and indicated that a small fraction of cells were resistant to SHM."( Response of 9L tumor cells in vitro to spirohydantoin mustard.
Bartle, PM; Deen, DF; Hoshino, T; Nomura, K; Williams, ME, 1979
)
0.26
" Injection of spiromustine on a split-dose schedule decreased the acute neurological toxicity in mice and allowed a larger total dosage to be delivered (compared to single bolus dosage)."( Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
Baker, LH; Corbett, T; Pazdur, R; Phillips, M; Redman, BG, 1987
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID153356Percent increase in life span of treated (5 mg/kg, day 1 only) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID211673Approximate number of tumor cells alive after administration (5 mg/kg, qd 1-9 days) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID211670Approximate number of tumor cells alive after administration (15 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153218Percent of deaths after administration (10 mg/kg, day 1 only) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153350Percent increase in life span of treated (10 mg/kg, day 1 only) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID153351Percent increase in life span of treated (10 mg/kg, qd 1-9 days) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153362Approximate log change after administration (10 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153332Percent of deaths after administration (5 mg/kg, day 1 only) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153354Percent increase in life span of treated (20 mg/kg, qd 1-9 days) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID211668Approximate number of tumor cells alive after administration (10 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153357Percent increase in life span of treated (5 mg/kg, qd 1-9 days) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153217Approximate number of tumor cells alive after administration (5 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153352Percent increase in life span of treated (15 mg/kg, day 1 only) mice as compared to the untreated leukemia controls; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153365Approximate log change after administration (5 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153333Percent of deaths after administration (5 mg/kg, qd 1-9 days) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153214Approximate number of tumor cells alive after administration (10 mg/kg, day 1 only) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153221Percent of deaths after administration (15 mg/kg, day 1 only) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID211669Approximate number of tumor cells alive after administration (10 mg/kg, qd 1-9 days) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID211671Approximate number of tumor cells alive after administration (20 mg/kg, qd 1-9 days) in normal mice; Expressed as therapeutic response1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153219Percent of deaths after administration (10 mg/kg, day 1 only) in normal mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153220Percent of deaths after administration (10 mg/kg, qd 1-9 days) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153225Percent of deaths after administration (20 mg/kg, qd 1-9 days) in leukemic mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID153222Percent of deaths after administration (15 mg/kg, day 1 only) in normal mice1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Isolation, synthesis, and antitumor evaluation of spirohydantoin aziridine, a mutagenic metabolite of spirohydantoin mustard.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (95.24)18.7374
1990's0 (0.00)18.2507
2000's1 (4.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]